

Press release 2014-09-15

WntR updates the patent situation for Foxy-5 and Box-5

WntResearch AB wishes to inform that the company has been granted five additional patents. For the company's product Foxy-5, we have received patent number 2 609 221 in Canada. For the company's product Box-5, we have received patent number 5 583 668 in Japan, patent number 2 517 190 in Russia and patent number ZL200980129491.7 in China. In addition, for Box-5 the European patent office has issued a decision to grant patent number 2 328 604, and this will take effect on 8 October 2014.

Patents for Foxy-5 have earlier been issued in Australia, Japan, Kina and the USA, and a patent for Box-5 has earlier been issued in the USA.

Hopefully further patents are about to be issued in Europe. As the company announced in June, the European Patent Office has issued a communication informing the company that it intends to grant patent No. 1 888 628 concerning peptides related to the company's product Foxy-5, but some actions from both the company and the European Patent Office still remains. With regards to the European application concerning i.a. Foxy-5, the situation is promising but the company has still not received any communication from the European Patent Office concerning an intention to grant the patent.

In addition, the company has several patent applications that are still pending at different patent offices. For Foxy-5 there is a patent application still pending in India, and for Box-5 there are patent applications pending in Canada and India.

VD Nils Brünner comments:

"We are very pleased that our patent strategy is progressing as planned."

For additional information please contact:

Nils Brünner, VD
E-post: nbr@wntresearch.com
Telefon: + 45 2614 4708

Om WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.